{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:07:48Z","timestamp":1789164468732,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["158989968 - SFB 900"],"award-info":[{"award-number":["158989968 - SFB 900"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.coi.2023.102305","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:14:16Z","timestamp":1679498056000},"page":"102305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["\u03b1\u03b2 and \u03b3\u03b4 T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients"],"prefix":"10.1016","volume":"82","author":[{"given":"Britta","family":"Eiz-Vesper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-514X","authenticated-orcid":false,"given":"Britta","family":"Maecker-Kolhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2023.102305_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coi.2023.102305_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.82","article-title":"EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management","volume":"47","author":"Ok","year":"2015","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.coi.2023.102305_bib3","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/j.1600-6143.2012.04197.x","article-title":"Pediatric heart transplant S: a 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients","volume":"12","author":"Chinnock","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib4","article-title":"Clinical utility of Epstein-Barr virus viral load monitoring and risk factors for posttransplant lymphoproliferative disorders after kidney transplantation: a single-center, 10-year observational cohort study","volume":"3","author":"Franceschini","year":"2017","journal-title":"Transpl Direct"},{"key":"10.1016\/j.coi.2023.102305_bib5","doi-asserted-by":"crossref","first-page":"604.e601","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey","volume":"21","author":"San-Juan","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coi.2023.102305_bib6","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2217\/imt.10.43","article-title":"Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation","volume":"2","author":"Shaffer","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coi.2023.102305_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705289","article-title":"Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development","volume":"37","author":"Weinstock","year":"2006","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2007.02080.x","article-title":"Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease\/lymphoma in children","volume":"8","author":"Bingler","year":"2008","journal-title":"Am J Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5500\/wjt.v6.i4.729","article-title":"Persistent Epstein-Barr viral load in Epstein-Barr viral naive pediatric heart transplant recipients: risk of late-onset post-transplant lymphoproliferative disease","volume":"6","author":"Das","year":"2016","journal-title":"World J Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib11","doi-asserted-by":"crossref","first-page":"e12875","DOI":"10.1111\/petr.12875","article-title":"Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy","volume":"21","author":"Kullberg-Lindh","year":"2017","journal-title":"Pedia Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02193","article-title":"The T-cell response to Epstein-Barr virus-new tricks from an old dog","volume":"10","author":"Long","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_sbref13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fmicb.2018.00416","article-title":"Emergence of CD4+ and CD8+ polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection","volume":"9","author":"Lam","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coi.2023.102305_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI10590","article-title":"CD8(+) T-cell selection, function, and death in the primary immune response in vivo","volume":"106","author":"Callan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2023.102305_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00382-17","article-title":"Asymptomatic primary infection with Epstein-Barr virus: observations on young adult cases","volume":"91","author":"Abbott","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2023.102305_bib16","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4049\/jimmunol.167.4.2019","article-title":"EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function","volume":"167","author":"Hislop","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002889","article-title":"Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years","volume":"8","author":"Klarenbeek","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102305_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003076","article-title":"The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age","volume":"8","author":"Lelic","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2023.102305_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nri.2015.3","article-title":"Tissue-resident memory T cells: local specialists in immune defence","volume":"16","author":"Mueller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib20","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1172\/JCI24810","article-title":"Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance","volume":"115","author":"Hislop","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2023.102305_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2003-06-1791","article-title":"Integration of apoptosis and telomere erosion in virus-specific CD8+ T cells from blood and tonsils during primary infection","volume":"103","author":"Soares","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_sbref22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33488-2","article-title":"Identification of distinct functional thymic programming of fetal and pediatric human gammadelta thymocytes via single-cell analysis","volume":"13","author":"Sanchez Sanchez","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2023.102305_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.4049\/jimmunol.1900592","article-title":"TCR sequencing reveals the distinct development of fetal and adult human Vgamma9Vdelta2 T cells","volume":"203","author":"Papadopoulou","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102305_sbref24","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf0125","article-title":"A fetal wave of human type 3 effector gammadelta cells with restricted TCR diversity persists into adulthood","volume":"6","author":"Tan","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876493","article-title":"Butyrophilins: gammadelta T cell receptor ligands, immunomodulators and more","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","article-title":"Targeted activation of human Vgamma9Vdelta2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease","volume":"26","author":"Xiang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coi.2023.102305_sbref27","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1084\/jem.20161017","article-title":"Two alternate strategies for innate immunity to Epstein-Barr virus: one using NK cells and the other NK cells and gammadelta T cells","volume":"214","author":"Djaoud","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2023.102305_sbref28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.celrep.2016.04.081","article-title":"RhoB mediates phosphoantigen recognition by Vgamma9Vdelta2 T cell receptor","volume":"15","author":"Sebestyen","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2023.102305_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-019-0118-2","article-title":"High-throughput analysis of the human thymic Vdelta1(+) T cell receptor repertoire","volume":"6","author":"Di Lorenzo","year":"2019","journal-title":"Sci Data"},{"key":"10.1016\/j.coi.2023.102305_bib30","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","article-title":"Human gammadelta thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling","volume":"192","author":"Ribot","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14760","article-title":"Clonal selection in the human Vdelta1 T cell repertoire indicates gammadelta TCR-dependent adaptive immune surveillance","volume":"8","author":"Davey","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2023.102305_sbref32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ni.3686","article-title":"Human gammadelta T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection","volume":"18","author":"Ravens","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/infdis\/161.5.1013","article-title":"Gamma delta T cell receptor-bearing lymphocytes during Epstein-Barr virus infection","volume":"161","author":"De Paoli","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2023.102305_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2249.2007.03388.x","article-title":"Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction","volume":"149","author":"Fujishima","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib35","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4049\/jimmunol.149.12.3984","article-title":"V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes","volume":"149","author":"Hacker","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212525","article-title":"A CMV-induced adaptive human Vdelta1+ gammadelta T cell clone recognizes HLA-DR","volume":"219","author":"Deseke","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2023.102305_bib37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ni.2394","article-title":"Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor","volume":"13","author":"Willcox","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba9010","article-title":"Human gammadelta T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2","volume":"6","author":"Harly","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib39","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2010-01-255166","article-title":"The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation","volume":"116","author":"Knight","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807765","article-title":"Evidence for an adult-like type 1-immunity phenotype of Vdelta1, Vdelta2 and Vdelta3 T cells in Ghanaian children with repeated exposure to Malaria","volume":"13","author":"Leon-Lara","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7430","article-title":"Repeated Plasmodium falciparum infection in humans drives the clonal expansion of an adaptive gammadelta T cell repertoire","volume":"13","author":"von Borstel","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2023.102305_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2249.1991.tb05612.x","article-title":"A subset of gamma delta lymphocytes is increased during HIV-1 infection","volume":"83","author":"De Paoli","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/v14010117","article-title":"The role of gammadelta T cells as a line of defense in viral infections after allogeneic stem cell transplantation: opportunities and challenges","volume":"14","author":"Janssen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.coi.2023.102305_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Disco"},{"key":"10.1016\/j.coi.2023.102305_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of gammadelta T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib46","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2023.102305_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005400","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia","volume":"10","author":"Sanchez Martinez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2023.102305_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","article-title":"Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gammadeltaT-cell receptor","volume":"118","author":"Marcu-Malina","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","article-title":"Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells","volume":"7","author":"Johanna","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2023.102305_bib51","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.coi.2023.102305_bib52","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib53","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000350331","article-title":"Posttransplant lymphoproliferative disorder in pediatric patients","volume":"80","author":"Hussein","year":"2013","journal-title":"Pathobiology"},{"key":"10.1016\/j.coi.2023.102305_bib55","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib56","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00467-019-04284-w","article-title":"Biomarkers for PTLD diagnosis and therapies","volume":"35","author":"Martinez","year":"2020","journal-title":"Pedia Nephrol"},{"key":"10.1016\/j.coi.2023.102305_bib57","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib58","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/TP.0b013e318279968d","article-title":"EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease","volume":"95","author":"Wilsdorf","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2023.102305_bib60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.trim.2006.10.006","article-title":"Quantitative analysis of EBV-specific CD4\/CD8 T cell numbers, absolute CD4\/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD","volume":"17","author":"Sebelin-Wulf","year":"2007","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib61","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/01.tp.0000290232.65830.e7","article-title":"A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease","volume":"84","author":"Guppy","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2023.102305_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2013.11.007","article-title":"Multimer monitoring of CMV-specific T cells in research and in clinical applications","volume":"78","author":"Borchers","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.coi.2023.102305_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2014.05.011","article-title":"Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches","volume":"408","author":"Tischer","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.coi.2023.102305_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/814973","article-title":"Posttransplant lymphoproliferative disease after pediatric solid organ transplantation","volume":"2013","author":"Mynarek","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00276","article-title":"Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Fuji","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_sbref66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10875-021-01205-1","article-title":"Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients","volume":"42","author":"Schulze Lammers","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2023.102305_sbref67","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/TP.0b013e3181d7c424","article-title":"Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up","volume":"90","author":"Haque","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2023.102305_bib69","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib70","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2023.102305_sbref71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01475","article-title":"Dissecting Epstein-Barr virus-specific T-cell responses after allogeneic EBV-specific T-cell transfer for central nervous system posttransplant lymphoproliferative disease","volume":"9","author":"Schultze-Florey","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib72","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_bib75","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2013.07.015","article-title":"CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome","volume":"19","author":"Sukdolak","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib76","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-014-0336-5","article-title":"Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells","volume":"12","author":"Tischer","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.coi.2023.102305_bib77","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2023.102305_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2023.102305_bib79","article-title":"Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry","volume":"3","author":"Eiz-Vesper","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2023.102305_bib80","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.coi.2023.102305_sbref81","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2023.102305_bib82","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2023.102305_bib83","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2023.102305_bib84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712590903456003","article-title":"Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation","volume":"10","author":"Leen","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coi.2023.102305_bib85","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2023.102305_bib86","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2013-12-547349","article-title":"Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy","volume":"124","author":"Stemberger","year":"2014","journal-title":"Blood"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791523000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:15:35Z","timestamp":1778562935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791523000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":86,"alternative-id":["S0952791523000249"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2023.102305","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b1\u03b2 and \u03b3\u03b4 T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2023.102305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102305"}}